Avatrombopag, a promising novel thrombopoietin receptor agonist for refractory/relapsed/intolerant non-severe aplastic anemia: a phase 2 single-arm clinical trial

Avatrombopag, a promising novel thrombopoietin receptor agonist for refractory/relapsed/intolerant non-severe aplastic anemia: a phase 2 single-arm clinical trial

AbstractIntroduction The therapeutic options for thrombocytopenia in non-severe aplastic anaemia (NSAA) are limited. Avatrombopag (AVA) is prescribed for thrombocytopenic diseases but not for NSAA.Methods Herein, we conducted a phase 2, non-randomized, single-arm trial to explore the efficacy and sa...

Full description

Bibliographic Details
Main Authors: Ziqi Wan, Miao Chen, Bing Han
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Annals of Medicine
Subjects:
Non-severe aplastic anemia
avatrombopag
efficacy
side effects
switch
Online Access:https://www.tandfonline.com/doi/10.1080/07853890.2023.2224044

Internet

https://www.tandfonline.com/doi/10.1080/07853890.2023.2224044

Similar Items